Skip to content

Reepaven effect on severity of pain and bleeding during menstruation

Investigation of the effect of Reepaven drug on severity of pain and bleeding during menstruation in women of childbearing age compared with placebo

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20140804018677N4
Enrollment
80
Registered
2020-06-03
Start date
2019-01-21
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Women with painful menstrual cramps or heavy bleeding.

Interventions

Intervention 1: Intervention group: Reepaven from Ghaem Darou Company (Persicaria bistorta, Quercus, Saccharum spontaneum and Punica granatum)
in the first two days of menstruation, 3 pills a day (after breakfast, lunch and dinner) and on the remaining days of the period, 2 pills daily (after lunch and dinner). Intervention 2: Control group:
in the first two days of menstruation, 3 pills a day (after breakfast, lunch and dinner) and on the remaining days of the period, 2 pills daily (after lunch and dinner).

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Painful menstrual cramps or heavy bleeding Aged 18-50years

Exclusion criteria

Exclusion criteria: Pregnancy and lactation Menopause Patients' reluctance to participate in the study Not taking the drug during the study period

Design outcomes

Primary

MeasureTime frame
The severity of the pain. Timepoint: baseline and end of study. Method of measurement: Women's Health Questionnaire.;Bleeding severity. Timepoint: baseline and end of study. Method of measurement: Women's Health Questionnaire.;The effect of disease severity on daily activity. Timepoint: baseline and end of study. Method of measurement: Women's Health Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoodeh Razghei Jahromi

Shahid Beheshti University of Medical Sciences

soodehrazeghi@gmail.com+98 21 22357

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026